$ACB reasons to buy: Aurora Cannabis still claims
Post# of 107468
(Total Views: 295)
Posted On: 04/20/2020 9:30:16 AM
$ACB reasons to buy: Aurora Cannabis still claims a sizable market share in the Canadian adult-use recreational cannabis market. The company is also a leader in the country's medical cannabis market. Outside of Canada, Aurora continues to be a top supplier to the German medical cannabis market.
The company's investments in technology and automation have also reaped benefits. Aurora boasts one of the lowest production costs in the industry. It also has a production capacity that leads the industry, although the company isn't currently operating at maximum throughput.
Probably the best argument for Aurora is that the global cannabis industry should still expand significantly over the next few years. The company's scale of operations, cost structure, and existing market share combine to give Aurora a launching pad that few others can claim to go after this big opportunity.
There's also Aurora's valuation. The pot stock trades at less than four times sales. While the COVID-19 outbreak is weighing on sales now, once the crisis is over cannabis sales should regain momentum. Some investors could find Aurora's low price-to-sales ratio along with the likelihood of rising sales in the future appealing.
The company's investments in technology and automation have also reaped benefits. Aurora boasts one of the lowest production costs in the industry. It also has a production capacity that leads the industry, although the company isn't currently operating at maximum throughput.
Probably the best argument for Aurora is that the global cannabis industry should still expand significantly over the next few years. The company's scale of operations, cost structure, and existing market share combine to give Aurora a launching pad that few others can claim to go after this big opportunity.
There's also Aurora's valuation. The pot stock trades at less than four times sales. While the COVID-19 outbreak is weighing on sales now, once the crisis is over cannabis sales should regain momentum. Some investors could find Aurora's low price-to-sales ratio along with the likelihood of rising sales in the future appealing.
(1)
(0)